[Clinical efficacy of fluconazole against fungal infections in hematological diseases].
Clinical efficacy of fluconazole was evaluated against fungal infections complicated with hematological diseases. Fluconazole 200 approximately 400 mg was administered intravenously to 20 suspected fungal infections occurring in patients with hematological diseases (acute leukemia 6, malignant lymphoma 11, adult T cell leukemia 2, chronic myelogenous leukemia blastic crisis 1). These mycoses included 8 cases of suspected pulmonary fungal infection, 10 cases suspected fungemia, and two cases of suspected hepatic fungal abscess. The clinical response rate was 60.0%. Side effects were observed in two cases, one with transient liver function test abnormality and the other with nausea. Fluconazole is considered to be a potent, safe antifungal agent for the treatment of suspected fungal infections associated with hematological diseases.
Morioka
E
E
First Department of Internal Medicine, School of Medicine, Fukuoka University.
Asahara
F
F
Nagano
M
M
Kawasaki
C
C
Yoshida
T
T
Uchida
T
T
Nakashima
H
H
Suzumiya
J
J
Kimura
N
N
Hisano
S
S
Okumura
M
M
D000328:Adult; D000935:Antifungal Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016469:Fungemia / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007938:Leukemia / Q000150:complications*; D008107:Liver Diseases / Q000188:drug therapy; D008172:Lung Diseases, Fungal / Q000188:drug therapy; D008223:Lymphoma / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000188:drug therapy*
D000935:Antifungal Agents; D015725:Fluconazole